medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


Implementación y monitoreo de la vacuna contra el VPH en América Latina

Luciani S, Bruni L, Agurto I, Ruiz-Matus C

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 683-692
Archivo PDF: 331.03 Kb.


RESUMEN

Objetivo. Describir las experiencias con la implementación, monitoreo y evaluación de programas de vacunación contra VPH en América Latina. Material y métodos. Revisamos datos publicados en revistas, informes gubernamentales, así como los informes de monitoreo de programas de inmunizaciones de la OPS/OMS/UNICEF y del centro de información del VPH del ICO/IARC. Resultados. Hasta diciembre de 2016, 13 países/territorios en América Latina (56%) han introducido vacunas contra VPH. La mayoría lo han hecho en los últimos tres años, apuntando a niñas de 10 a 12 años con un calendario de dos dosis, a través de programas escolares. La cobertura de vacunas varía entre 30 y 87%. La vigilancia de la seguridad está bien establecida, pero el monitoreo del impacto de la vacuna no, y los datos no están disponibles. Conclusiones. Aunque América Latina es la región en desarrollo más avanzada en la introducción de la vacuna contra VPH, los sistemas para su monitoreo son débiles y hay una escasez de datos de cobertura disponibles. Sigue habiendo desafíos para introducir vacunas contra VPH en varios países, para lograr una alta cobertura y para fortalecer el monitoreo, la evaluación y la presentación de informes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pan American Health Organization. Plan of Action on Immunization. Report to the 54th Directing Council [Internet]. 2015 [cited 2016 Dec 3]. Available from: http://www.paho.org/hq/index.php?option=com_content& view=article&id=11087&Itemid=41537&lang=en

  2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013 [cited 2016 Dec 3]. Available from: http:// globocan.iarc.fr

  3. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prevention Research. 2012;5(1):18-23. https://doi.org/10.1158/1940-6207. CAPR-11-0542

  4. Brotherton JML, Zuber PLF, Bloem PJN. Primary prevention of HPV through vaccination: Update on the current global status. Curr Obstet Gynecol Rep. 2016;5(3):210-23. https://doi.org/10.1007/s13669-016- 0165-z

  5. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2016 conclusions and recommendations. Wkly Epidemiol Rec. 2016;48(2):579-80. [cited 2016 Dec 27]. Available from: http://apps.who.int/iris/bitstream/10665/251816/1/ WER9148_561-582.pdf?ua=1

  6. World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84(15):118-31.

  7. Pan American Health Organization. Final report of the XXI Technical Advisory Group Meeting on Vaccine-preventable Diseases of the Pan American Health Organization. 2013. [cited 2016 Dec 3]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id =1862&Itemid=2032&lang=en

  8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosc FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Health. 216;4(7):453-63. https://doi.org/10.1016/S2214-109X(16)30099-7

  9. Pan American Health Organization. Health Situation in the Americas: Core Indicators 2016. Washington, DC, USA: PAHO, 2016

  10. World Health Organization. Report of the meeting on HPV vaccine coverage and impact monitoring [Internet]. 2010 [cited 2016 Dec 22] Available from: http://www.who.int/immunization/hpv/learn/hpv_vaccine_ coverage_and_impact_monitoring_report_who_2009.pdf

  11. Catalan Institute of Oncology (ICO)/International Agency for Research on Cancer (IARC), Information Centre on HPU and Cancer.2017 Statistics. Barcelona, Spain: ICO/IARC [cited December 3, 2016]. Available at: http:// www.hpvcentre.net/datastatistics.php

  12. Murillo R, Herrero R, Sierra MS, Forman D. Cervical cancer in Central and South America: Burden of disease and status of disease control. Cancer Epidemiology. 2016;44(Suppl 1):S121-30. https://doi.org/10.1016/j. canep.2016.07.015

  13. de Oliveira LH, Toscano CM, Sanwogou NJ, Ruiz-Matus C, Tambini G, Roses-Periago M, et al. Systematic documentation of new vaccine introduction in selected countries of the Latin American Region. Vaccine. 2013;31(Suppl 3):C114-22. https://doi.org/10.1016/j.vaccine.2013.05.032

  14. Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ. National decisionmaking on adopting new vaccines: A systematic review. Health Policy Plan. 2011;27(Suppl 2):39-49.

  15. Jauregui B, Janusz CB, Clark AD, Sinha A, Garcia AG, Resch S, et al. ProVac Global Initiative: A vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015;33(Suppl 1):A21-7. https:// doi.org/10.1016/j.vaccine.2014.12.080

  16. Piñeros M, Cortés C, Trujillo L, Wiesner C. Conocimientos, aceptabilidad y actitudes sobre la vacuna contra el VPH en médicos generales, ginecólogos y pediatras en Colombia. Rev Colomb Cancerol. 2009;13(2):88-98.

  17. Mazzadi A, Paolino M, Arrossi S. HPV vaccine acceptability and knowledge among gynecologists in Argentina. Salud Publica Mex. 2012;54(5):515-22. https://doi.org/10.1590/S0036-36342012000500008

  18. World Health Organization. Global Vaccine Action Plan 2011-2020 [Internet]. 2013 [cited 2016 Dec 3]. Available from: http://www.who.int/ immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/

  19. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821-30. https://doi.org/10.2471/BLT.11.089862

  20. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects. Vaccine. 2013;31(37): 3811-7. https:// doi.org/10.1016/j.vaccine.2013.06.016

  21. Gollust SE, LoRusso SM, Nagler RH, Fowler EF. Understanding the role of the news media in HPV vaccine uptake in the United States: Synthesis and commentary. Hum Vaccin Immunother. 2016;12(6):1430-4. https://doi. org/10.1080/21645515.2015.1109169

  22. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school based immunization program. Vaccine. 2014;32(3):320-6. https://doi.org/10.1016/j.vaccine.2013.11.070

  23. Ropero-Álvarez AM, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C, Tambini G. Vaccination Week in the Americas: An Opportunity to integrate other health services with immunization. J Infect Dis. 2012;205(Suppl 1):S120-5. https://doi.org/10.1093/infdis/jir773

  24. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clinical Infectious Diseases. 2016;63(15):519-27. https://doi.org/10.1093/cid/ciw354




2020     |     www.medigraphic.com